Articles

Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition

Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston
Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston
Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston
Department of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston
Department of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston
Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston
Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston
Department of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston
Bioscience Oncology RandD, AstraZeneca, Boston
Bioscience Oncology RandD, AstraZeneca, Boston
Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston
Haematologica Early view Dec 23, 2020 https://doi.org/10.3324/haematol.2020.260331